In Brief: Summit Technology v. Chiron Technolas GmbH
This article was originally published in The Gray Sheet
Executive SummarySummit Technology v. Chiron Technolas GmbH: Chiron Technolas appeals German court ruling that the firm's Keracor 116 and Schwind GmbH's Keratom ophthalmic excimer laser systems infringe a Summit patent ("The Gray Sheet" Sept. 4, p. 14). Chiron Technolas is prohibited from manufacturing, selling or using the laser systems in Germany following the posting of a bond by Summit that was necessary for enforcement of an injunction issued by the German court. In addition to the appeal, Chiron Technolas has also filed a nullity action with the German patent office, Summit states. Schwind also plans to file an appeal. Coherent, which distributes the Schwind laser, states that no interruptions in product availability are anticipated since its laser can be offered with a newly developed optical delivery system that does not infringe "whenever it becomes necessary to do so," Coherent states...
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.